Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- May 28, 2014-- Pediatric Patients Aged 1 Month to Less Than 17 Years Now Have A New Option to Help Prevent Acute Chemotherapy-Induced Nausea and Vomiting --
Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of ALOXI® (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with...
- May 22, 2014- Companies Advance Multiple Co-discovery Programs for First-in-class Targets in Oncology -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita (PL: SLV), one of the largest drug discovery companies...
- May 15, 2014Obesity Education Network Provides Tools to Help Physicians Assess and Manage Patients Who are Overweight or Obese
Eisai Inc. today announced the launch of a website that will provide physicians with access to comprehensive clinical information that addresses obesity screening and risk assessment,...
-
May 14, 2014Data underscore breadth of oncology portfolio
Eisai Inc. announced today that 10 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in...
- May 9, 2014Expansion Enables Eisai to Reach 90,000 Healthcare Providers
Eisai Inc. announced today it will add more than 200 new contract sales representatives to its Metabolic Business Unit, bringing the total sales force for BELVIQ® to approximately 600, triple the...
- Apr 29, 2014-- Doctors Can Help Patients Set Personal Weight Loss Goals: It's Not a One Size Fits All Approach --
Eisai Inc. today announced the launch of My Healthy™, an interactive and motivational campaign that shifts the focus of the obesity conversation away from just pounds lost to health gained....
- Apr 25, 2014
Eisai Inc. announced today that six abstracts highlighting data analyses for FYCOMPA™ (perampanel) will be presented at the 66th annual American Academy of Neurology (AAN) meeting, taking place...
-
Apr 14, 2014- Campaign Creates Awareness of Prescription Drug Option for Chronic Weight Management -
Eisai Inc. today announced the launch of a new national television advertising campaign for BELVIQ® (lorcaserin HCl) CIV, an FDA-approved prescription therapy
- Apr 3, 2014- Company to Present Data on SF3B1 Program at a Symposium During the American Association for Cancer Research Annual Meeting 2014 -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision medicines for oncology, announced today...
-
Mar 31, 2014
Eisai Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., today announced the sale and assignment of its rights to a worldwide exclusive license...
